An all-in-one AAV vector for cardiac-specific gene silencing by an adenine base editor

分享:

简介:

  • 作者: Zhanzhao Liu, Luzi Yang, Yuhan Yang, Jiting Li, Zhan Chen, Congting Guo, Qianhao Guo, Qiuxuan Li, Yueshen Sun, Dongyu Zhao, Xiaomin Hu, Fei Gao and Yuxuan Guo
  • 杂志: BioRxiv
  • Doi: https://www.doi.org/10.1101/2024.09.30.615742
  • 出版日期: 2024 Sep 30

论文中使用的产品/服务

Quotation shows PackGene:We thank PackGene Biotech for AAV production and GenePlus for next-generation sequencing.

Research Field:cardiac gene therapy

AAV Serotype:AAV9

Targeted organ:ventricles

Animal or cell line strain:mice

询价

摘要

ABE editing outcomes are highly variable and unpredictable, depending on various factors. Therefore, the success rate of creating targeted A•T-to-G•C conversions using ABE is not high. But utilizing ABE to target RNA splicing sites for gene silencing has a higher success rate. Another challenge for base editing in the heart is that traditional ABE is too large in size, necessitating dual AAV delivery. Whether single AAV delivery can be achieved remains to be explored. In this study, we demonstrated how the diversity of Cas9 homologs and screening of sgRNAs can facilitate cardiac base editing. Single-AAV base editing outperformed dual-AAV systems in the heart, potentially benefiting from chromatin accessibility-guided sgRNA selection. These findings have important implications for the development of more effective and predictable base editing tools for cardiac gene therapy.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载